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Objective: Improving health-related quality of life (HRQL) is the main goal of surgery to treat peripheral vascular disease
(PVD); however, HRQL is rarely measured directly. Rather, most surgeons use other measures, such as patient symptoms
and ankle-brachial index (ABI) to determine the need for intervention in PVD. The accuracy of these surrogates in
representing HRQL has been untested. The purpose of this study was to determine the correlation of these measures with
HRQL in patients undergoing evaluation for intervention in symptomatic PVD.
Methods: Patients (n 108) referred to the vascular surgery service with symptoms of PVD were enrolled in a prospective
study of HRQL. Patients completed two validated HRQL questionnaires: the short form-36 (SF-36) and the Walking
Impairment Questionnaire (WIQ). All patients had symptoms consistent with PVD, including claudication (n  69;
63.9%), ischemic rest pain (n  17; 15.7%), or tissue loss (n  22; 20.4%). ABI was measured at presentation.
Results: The mean ABI was 0.53 (range, 0.00-0.98). The maximal correlation between SF-36 score and ABI was reflected
in the Physical Component Summary score (r  0.25). WIQ score also exhibited modest correlation with ABI, with
maximal correlation noted for stair climbing (r  0.26). Both SF-36 and WIQ scores exhibited a highly significant
association with symptoms. Patients with more severe symptoms, such as lifestyle-limiting claudication or limb-
threatening ischemia, had lower HRQL scores compared with patients with non-lifestyle-limiting claudication. Multi-
variate analysis demonstrated that SF-36 and WIQ physical summary scores are better predicted by symptoms than by
ABI (P < .01).
Conclusions: HRQL in patients with PVD correlates weakly with ABI, but exhibits a closer association with vascular
symptoms. However, neither variable fully expresses patient HRQL. These data suggest that sole reliance on these
surrogates may not accurately reflect the effect of PVD on HRQL, or the potential benefit of vascular surgery in
improving HRQL. (J Vasc Surg 2004;39:723-7.)The traditional objectives of intervention in patients
with peripheral vascular disease (PVD) have been symp-
tomatic relief and limb salvage.1,2 In recent years the im-
portance of functional outcome after intervention has been
recognized as an important end point.3 Although limb
salvage and improving functional status are the stated goals
of intervention in PVD, the importance of these therapeu-
tic goals lies in their potential for improving health-related
quality of life (HRQL).4-6 In lieu of direct measures of
baseline HRQL, physicians routinely rely on subjective
patient symptoms and ankle-brachial index (ABI) to iden-
tify appropriate candidates for intervention. However, the
ability of these measures to act as surrogates for HRQL is
questionable.7-9 The purpose of this study was to examine
the relationship between symptoms, ABI, and two different
scales for measurement of HRQL to determine whether
these clinical parameters accurately reflect HRQL.
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Study population. This was a prospective cohort
study for the purpose of measuring HRQL in patients with
PVD at a single institution, and was approved by the
institutional review board. Over 7 months, from December
2002 to June 2003, 124 outpatients in the vascular surgery
clinic at the Dallas Veterans Affairs Medical Center agreed
to participate in the study. Twelve patients were subse-
quently excluded after further examination determined that
their symptoms were not consistent with PVD. Four pa-
tients were excluded because of clinical dementia, signifi-
cant mental retardation, or concurrent treatment with nar-
cotic analgesics. Resting ABIs were obtained in the
remaining 108 patients. Four patients were excluded be-
cause of normal ABI ( 1.0) with triphasic Doppler wave-
forms. ABIs were obtained by registered vascular technol-
ogists using an Imex Lab 9100 vascular diagnostic system
(Nicolet Vascular, Madison, Wis). ABI was calculated for
each symptomatic extremity, with the highest Doppler-
derived systolic pressure at the ankle (dorsalis pedis or
posterior tibialis artery), indexed to the highest Doppler-
derived brachial artery pressure. Symptoms at presentation
were categorized as claudication (n  69; 63.9%) or limb-
threatening ischemia (n  39; 36.1%). Limb-threatening
ischemia was defined as the presence of ischemic rest pain (n
 17; 15.7%) or tissue loss (n 22; 20.4%). Patients in this723
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limb salvage. Claudication was designated as lifestyle-lim-
iting (n  19; 17.6%) by the clinician if it interfered with
the patient’s ability to maintain economic viability, such as
the ability to remain employed. In retired or unemployed
patients, alternate criteria for the designation of lifestyle-
limiting claudication were used, such as the ability to per-
form basic functions necessary for subsistence. An example
of lifestyle-limiting claudication in a retired person would
include inability to participate in a standard cardiac rehabil-
itation program. In the absence of these criteria, claudica-
tion was designated as non-lifestyle-limiting (n  50;
46.3%). The designation of lifestyle-limiting versus non-
lifestyle-limiting claudication was made by surgeons not
involved in the study and who were blinded to the results of
HRQL questionnaires.
Data collection. In addition to symptoms of PVD,
demographic data (age and gender) and risk factors for
PVD were noted, including diabetes mellitus, hyperten-
sion, smoking, and hypercholesterolemia. Other comorbid
conditions with potential to influence HRQL were also
identified, including ischemic heart disease, history of cere-
brovascular accident (CVA), chronic obstructive pulmo-
nary disease (COPD), osteoarthritis, and end-stage renal
disease. In addition, a history of vascular surgery, previous
contralateral lower extremity amputation, ambulatory sta-
tus (ambulatory, ambulatory with assistance, nonambula-
tory), and living status (independent, with assistance, full-
care facility) were documented. ABI was obtained in all
patients.
HRQL questionnaires. Patients completed two
questionnaires at enrollment: a generic HRQL measure,
the short-form 36 (SF-36),10 and a disease-specific func-
tional measure, the Walking Impairment Questionnaire
(WIQ). The SF-36 is an extensively validated, self-admin-
istered questionnaire, which was developed to measure
eight categories of HRQL: Physical Functioning, Role
Physical, Body Pain, General Health, Vitality, Role Emo-
Table I. Peripheral vascular disease risk factors and
comorbid conditions
Comorbidities n %
Hypercholesterolemia 90 83.3
Hypertension 85 78.8
Recent smoking history 79 73.1
Current smoking history 57 52.8
Diabetes mellitus 39 36.1
Ischemic heart disease 55 50.9
Previous lower extremity vascular
surgery
53 49.1
Lower extremity arthritis or back
pain
33 30.6
Chronic obstructive pulmonary
disease
30 27.8
Cerebrovascular accident 27 25.0
Previous contralateral
amputation
8 7.4
End-stage renal disease 5 4.6tional, Social Functioning, and Mental Health. The SF-36
questionnaire is self-administered, and each category is
scored on a scale of 0 to 100. Two standardized summary
scores provide a concise approximation of the physical and
mental components of HRQL. The Physical Component
Score is composed of Physical Functioning, Role Physical,
Body Pain, and General Health scales. The Mental Com-
ponent Score is obtained by summating Vitality, Role
Emotional, Social Functioning, and Mental Health. High
scores in each category are associated with improved
HRQL.10
The WIQ was used as a functional, disease-specific
HRQL measure. This questionnaire has been validated via
correlation with treadmill walking.11,12 The WIQ measures
four walking components, scored from 0 to 100, in patients
with PVD: reported Symptom Severity, Walking Distance,
Walking Speed, and Stair Climbing. High scores are asso-
ciated with milder symptoms and better function. This
questionnaire has not been validated in a self-administered
setting, so it was administered by a proctor who read each
question and the possible responses to the patient. All
proctors had extensive experience in administering quality-
of-life questionnaires, including the WIQ.
Statistical analysis. Continuous data were expressed
as mean SEM. Differences in HRQL, stratified by symp-
tom category, were tested via the Student t test. Pearson
and Spearman rho bivariate correlations were used to ex-
amine the relationship between patient ABI and HRQL
scores, as reported with the SF-36 and WIQ. Linear regres-
sion analysis was used to assess the significance of the
association of ABI or symptoms to HRQL and to explain
the variance in HRQL scores. All statistical calculations
were performed with SPSS version 11.0 (SPSS, Chicago,
Ill).
RESULTS
Patient data. The average age of respondents was 65
 0.87 years (range, 43-86 years). One hundred seven
patients (99%) were men; one patient (1%) was a woman.
Sixteen patients (14.8%) were African American. Risk fac-
tors and comorbid conditions are outlined in Table I.
Most patients (n  103; 95.4%) were ambulatory, and
96 of 108 patients (90.6%) lived independently. Of the 108
Table II. Correlation between HRQL and ABI*
Summary scores
Correlation
coefficient
SF-36 PCS r  0.25
SF-36 MCS r  0.01
WIQ SS r  0.14
WIQ WD r  0.13
WIQ WS r  0.23
WIQ SC r  0.26
HRQL, Health-related quality of life; ABI, ankle-brachial index; SF-36,
short form, 36 items; PCS, physical Component Score; MCS, Mental
Component Score; WIQ, Walking Impairment Questionnaire; SS, Symptom
Severity; WD, Walking Distance; WS, Walking Speed; SC, Stair Climbing.
*Pearson correlation.
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claudication and 39 patients (36.1%) had limb-threatening
ischemia; the remaining 50 patients (46.3%) had non-
lifestyle-limiting claudication. The average ABI was 0.53
0.02 (range, 0.00-0.98). For patients with non-lifestyle-
limiting claudication, the mean ABI was 0.61  0.03
(range, 0.24-0.98). Patients with lifestyle-limiting claudi-
cation had a mean ABI of 0.53 0.02 (range, 0.45-0.90),
and patients with limb-threatening ischemia had a mean
ABI of 0.44  0.02 (range, 0.00-0.78).
HRQL. The SF-36 questionnaire was incomplete for
14 patients (13.0%). There was sufficient data in 11 of these
cases (categorical missed items 50% of total) to replace
missing data by simple mean imputation.13-16 In three
cases (2.8%) sufficient data were missing from the SF-36
(categorical missed items 50% of total) to warrant exclu-
sion.17 In addition, two incomplete WIQs (1.9%) were
excluded from analysis because of excessive missing data.
The mean Physical Component Score was 27.3 0.83,
compared with a published mean value of 42.3 for age-
matched persons with uncomplicated hypertension and no
overt PVD.10 By comparison, a previous study by Feinglass
et al9 noted a mean ( SD) PF score of 45.1  0.96 for
patients with PVD with hypertension, compared with 29.6
 2.1 in the present study. This unfavorable comparison
for PVD versus age-matched population norms and pa-
tients without PVD with similar comorbid conditions is
consistent with previous studies.2,18 The mean Walking
Distance and Walking Speed scores were 7.5  1.29 and
7.9  1.01, respectively.
ABI and HRQL. The correlation between ABI and
HRQL is shown in Table II. In correlating SF-36 scores
with ABIs, the greatest correlation coefficient was found for
Physical Component Score (r  0.25). As expected, no
significant correlation existed between the emotional com-
ponents of the SF-36 and ABI. A modest correlation was
noted for ABI and WIQ Stair Climbing (r  0.26). Non-
parametric comparisons were also performed with the
Spearman rho, and did not differ significantly form the
parametric bivariate correlations reported above.
Table III. Univariate comparison of HRQL and
symptom categories
Summary
scores
Non-lifestyle-
limiting
claudication
(n  50)
Lifestyle-limiting
claudication or
limb-threatening
ischemia (n  58) P*
SF-36 PCS 30.7  1.18 24.3  1.02 .001
SF-36 MCS 47.5  1.74 43.5  1.70 .11
WIQ SS 35.7  3.42 22.4  2.93 .004
WIQ WD 12.6  2.53 3.1  0.66 .001
WIQ WS 11.7  1.75 4.6  0.94 .001
WIQ SC 25.0  3.47 10.7  2.24 .001
HRQL, Health-related quality of life; PCS, Physical Component Score;
MCS, Mental Component Score; WIQ, Walking Impairment Questionnaire;
SS, Symptom Severity, WD, Walking Distance; WS, Walking Speed; SC, Stair
Climbing.
*Student t test.Symptoms and HRQL. The univariate relationship
between symptoms and HRQL, as measured by the SF-36
and the WIQ, is shown in Table III. The Physical Compo-
nent Score of the SF-36 and all four WIQ summary scores
indicated a significantly greater HRQL in patients with
non-lifestyle-limiting claudication compared with patients
with lifestyle-limiting claudication or limb-threatening
ischemia. There was no association between symptoms and
the Mental Component Score of the SF-36.
The relationship of symptom categories and ABI to
HRQL scores, with linear regression, is shown in Table IV.
In each case HRQL was more closely associated with
symptom categories than ABI. The negative regression
coefficient values for these summary scores indicate that
HRQL scores decrease as severity of symptoms increases
(lifestyle-limiting claudication or limb-threatening isch-
emia vs non-lifestyle-limiting claudication). These results
suggest that a typical patient with non-lifestyle-limiting
claudication will have a 5.9 point higher SF-36 Physical
Component Score than a similar patient with lifestyle-
limiting claudication or limb-threatening ischemia. Ad-
justed r2 values ranged from 0.04 to 0.16, indicating that
84% to 96% of the variance in these HRQL summary scores
was not explained by either symptom severity or ABI.
When ischemic heart disease, COPD, and CVA were simul-
taneously included as covariates in the regresssion analysis,
the r2 values increased slightly to account for 10% to 19% of
the variance in HRQL.
DISCUSSION
The goal of surgical intervention in patients with PVD
is to improve functional status by improving distal perfu-
sion.19-21 Patients are selected for intervention in part on
the basis of severity of functional limitations, such as life-
style-limiting claudication, or potential for limb loss. Im-
plicit in the decision to pursue intervention for PVD are the
assumptions that symptoms and ABIs accurately reflect
HRQL and that intervention will improve the HRQL.
However, evidence to support these assumptions is scant.
Direct measurements of HRQL in patients with PVD
have been relatively uncommon. Feinglass et al9 reported a
Table IV. Multivariate relationship of HRQL to
symptom categories and ABI
Dependent
variable*
Symptoms
coefficient ABI coefficient r2
SF-36 PCS 5.9; p  .001 5.2; p  .14 .16
SF-36 MCS 6.3; p  .02 3.3; p  .57 .04
WIQ SS 13.1; p  .008 6.6; p  .53 .07
WIQ WD 9.3; p  .001 1.6; p  .78 .11
WIQ WS 6.4; p  .003 6.7; p  .14 .12
WIQ SC 13.6; p  .002 15.7; p  .09 .14
HRQL, Health-related quality of life; ABI, ankle-brachial index; SF-36,
short form, 36 items; PCS, Physical Component Score; MCS, Mental
Component Score; SS, Symptom Severity; WD, Walking Distance; WS,
Walking Speed; SC, Stair Climbing.
*Multivariate linear regression analysis.
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Physical Functioning. Currie et al20 and Pell et al22 showed
an early increase in SF-36 Physical Function and Body Pain
scores 3 to 6 months after angioplasty or surgical revascu-
larization, compared with exercise therapy. Chetter et al23
noted that Physical Function, Body Pain, Vitality, and
Social Function scores all increased if infrainguinal grafts
remained patent for at least 6 months after surgery. Simi-
larly, Bosch25 found improved HRQL, as measured by the
SF-36, 24 months after surgery. Two additional studies
reported an increase in WIQ Walking Distance and Walk-
ing Speed after surgery.19,25 An additional longitudinal
follow-up study by Feinglass et al26 showed that post-
intervention Physical Function and Walking Distance
scores improved as a result of revascularization. These
studies confirmed that surgical intervention increases
HRQL in patients with PVD after intervention. With the
exception of the Feinglass study, however, most studies
have focused on outcomes after intervention without in-
cluding baseline assessment or complete SF-36 and WIQ
questionnaires.
The purpose of the present study was to assess the
correlation between baseline HRQL assessments and the
two surrogates for HRQL commonly used in clinical deci-
sion-making in patients with PVD: symptoms and ABI. A
strong correlation between these clinical parameters and
quality of life would suggest that patient symptoms and
ABIs were valid surrogates and would obviate the need for
direct HRQL measurement. To assess quality of life in our
population we used both a generic HRQL measure (SF-36)
and a disease-specific functional questionnaire (WIQ).
These instruments have been validated through widespread
use in this population.19,20,22-25 Use of a broad baseline
assessment of HRQL ensured that quality of life was mea-
sured from both a global and a disease-specific, functional
perspective. This approach was designed to optimize the
likelihood of identifying potential correlations between
clinical parameters and HRQL.
In the present study we noted a modest correlation
between symptoms at presentation and the summary scores
for both the SF-36 and the WIQ. A smaller correlation was
noted when ABIs were compared with the same scores.
Although few studies to date have attempted to correlate
symptoms of PVD with HRQL at diagnosis, studies by
Feinglass et al9 and Kazmers et al2 noted a similar degree of
correlation between the SF-36 Physical Function and ABI.
In this multivariate analysis only the symptom category was
significantly associated with HRQL score at initial vascular
evaluation. This association was represented by consistently
negative regression coefficients, indicating that lifestyle-
limiting claudication and limb-threatening ischemia are
inversely related to HRQL scores on both questionnaires.
However, only a small percentage of the variance in HRQL
was predicted by either ABIs or symptoms. This percentage
did not improve dramatically when ischemic heart disease,
COPD, and CVA were included in the analysis as related
comorbid conditions. Previous studies have also addressed
the potential contribution of additional comorbid condi-tions to HRQL in patients with vascular disease with similar
findings.9,25 Feinglass et al,9 for example, reported a model
with nine different variables (including lowest leg ABI,
COPD, congestive heart failure or coronary artery disease,
and arthritis), and were only able to account for 14.5% of
the variance in SF-36 Physical Functioning score.
The practical significance of this information is twofold.
First, it suggests that even highly successful vascular inter-
ventions may not always result in dramatic improvement in
HRQL. For example, a patient with lifestyle-limiting clau-
dication and a low baseline HRQL owing to other comor-
bid conditions is not likely to realize a dramatic improve-
ment in HRQL despite technical success of an intervention.
Second, it suggests that the current surrogates for HRQL
are, at best, imperfect and that direct measurement of
HRQL is necessary to better quantify changes in HRQL
after therapeutic intervention. The data appear to validate
the clinical definition of lifestyle-limiting versus non-life-
style-limiting claudication used in the present study, since
the Physical Component Score of the SF-36 and the WIQ
summary scores were higher in patients with non-lifestyle-
limiting claudication compared with patients with lifestyle-
limiting claudication.
There are several inherent limitations to this study.
These data represent a single institution experience with a
relatively small number of patients; therefore the results
may not be generalized to the population at large. The
patient population represented was primarily elderly, male,
and white, with multiple comorbid conditions. In a popu-
lation with fewer comorbid conditions it is possible that
there is greater correlation between symptoms, ABI, and
HRQL. In addition, this study was designed to examine the
relationship of symptoms and ABIs to HRQL at a single
point in time. As such, this study cannot address the utility
of these surrogates in predicting changes in HRQL as a
result of intervention. A longitudinal study will be required
to correlate baseline symptoms and ABIs with HRQL after
therapy. Two such studies have been reported to date. A
study by Regensteiner et al19 with 14 patients showed an
increase in treadmill walking capacity and in WIQ Walking
Distance and Walking Speed scores after intervention, al-
though these measures of HRQL did not correlate with the
modest improvement in ABIs noted after intervention. A
larger study by Feinglass et al26 reported a modest increase
in ABIs after intervention that was associated with a lasting
improvement in SF-36 Physical Functioning score.
In conclusion, HRQL correlates weakly with ABIs, but
exhibits a closer association with vascular symptoms; how-
ever, neither variable fully expresses patient HRQL. These
data suggest that sole reliance on these clinical surrogates
for HRQL may not accurately reflect the effect of PVD on
HRQL or the potential benefit of vascular surgery in im-
proving HRQL. Direct measurements of HRQL at base-
line and after intervention may be useful as an additional
criterion for judging clinical outcomes of therapy for PVD.
At this time the role of HRQL measurement in clinical
decision-making remains undefined, but warrants further
investigation.
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